Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews Q2 Revenues Fall 38 Percent, Net Loss Narrows

NEW YORK (GenomeWeb News) - GeneNews today said second-quarter revenues tumbled 38 percent as R&D spending dropped 16 percent and net loss decreased by 7 percent.
 
Total receipts for the three months ended June 30 decreased to CA$540,000 (US$508,700) from CA$873,000 year over year.
 
The Toronto-based company said all its revenue for the second quarter of 2007 came from a $2 million prostate cancer biomarker research project it signed with an Asian biomedical consortium that it disclosed yesterday. Revenue for the prior-year period resulted from a collaboration agreement with Pfizer that ended in the first fiscal quarter of 2007.
 
R&D spending decreased to CA$1.8 million from CA$2.1 million year over year.
 
Net loss dipped to CA$1.8 million from CA$1.9 million in the year-ago period.
 
GeneNews said it had around CA$16.6 million in cash and cash equivalents as of June 30.
 
The company, which said its focus is currently on biomarker research and development for diagnostic products, did not offer revenue projections for the full year.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.